Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.
With the support of the Pamela and David Ott Fund and the John M. O'Quinn Foundation, The Pamela and David Ott Center of Excellence in Heritable Disorders of Connective Tissue and Ehlers-Danlos ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback